Regeneron's Libtayo approved as first-line advanced NSCLC treatment with chemotherapy
Iryna Drozd


The US FDA has approved an additional indication for Regeneron Pharmaceuticals' (NASDAQ:REGN) Libtayo, this time as a first-line treatment in advanced non-small cell lung cancer (NSCLC) in combination with platinum-based chemotherapy.
The indication is for patients with no EGFR, ALK or ROS1 aberrations and have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation

Regeneron (REGN) noted that the combination can be used in patients no matter their PD-L1 expression.
Libtayo (cemiplimab) was already approved in 1L advanced NSCLC as a monotherapy in patients with high PD-L1 expression.
Check out why Seeking Alpha contributor Edmund Ingham rates Regeneron (REGN) a hold.